This webinar will provide health care providers with information and knowledge on how to answer questions that patients may have about narrow therapeutic index (NTI) generic drugs, such as how the FDA recognizes the importance of bioequivalence in NTI generic drugs and has stricter standards for bioequivalence of NTI drugs than for other generic drugs. The presentation will also give providers information on FDA’s post-market research efforts to ensure therapeutic equivalence of generic NTI drugs.